Related Experiment Video
Updated: Sep 13, 2025

Author Spotlight: Unveiling the Role of SNF2L in Replication Fork Stability and Genome Duplication
Published on: August 23, 2024
All roads lead to mitosis: A common requirement for DNA replication stress-dependent and -independent killing of
Sebastian Omar Siri1, Ariel Abramovici Blasco1, Ginette Moyano1
1Cell Cycle and Genome Stability Laboratory, Fundación Instituto Leloir, Buenos Aires C1405 BWE, Argentina; Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires C1405 BWE, Argentina.
Abstract:
The deficiency in breast cancer associated proteins 1 and 2 (BRCA1 and 2) causes an early and more frequent onset of tumor genesis and progression. Poly (ADP-ribose) polymerase inhibitors (PARPi) are selectively toxic towards BRCA1 and 2-deficient tumors, sparing the healthy cells from patients from side effects. In BRCA1 and 2 deficient tumors, PARPi-mediated cell death is characterized by the augmentation of replication stress (RS) and chromosome instability (CIN) including micronuclei (MN) accumulation, a source of swift genomic rearrangements. PARPi also cause resistance to treatments which indicates the need of treatment alternatives. In this review, we discuss potential options that, similarly to PARPi, selectively kill BRCA1 and/or 2 deficient tumors. Remarkably, while many of those alternatives also upregulate MN and other CIN variables, others cause a RS-independent and MN-independent cell killing. This is the case of the inhibitors of Rho-kinase (ROCK) and, potentially, mitotic kinase Polo like kinase 1 (PLK1). Such a mode of cell killing could be advantageous if attempting to either prevent or postpone the rise of resistance clones in the tumor population that survives the treatment.
Insights
Targeting BRCA1/2-deficient tumors with PARP inhibitors (PARPi) can lead to resistance. This review explores alternative treatments, including ROCK and PLK1 inhibitors, that may overcome resistance by inducing cell death independently of replication stress or chromosome instability.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- BRCA1 and BRCA2 (Breast cancer genes 1 and 2) mutations lead to early-onset tumors.
- Poly (ADP-ribose) polymerase inhibitors (PARPi) selectively target BRCA1/2-deficient tumors but can cause treatment resistance.
- PARPi induce cell death via replication stress and chromosome instability, including micronuclei accumulation.
Purpose of the Study:
- To review alternative therapeutic strategies for BRCA1/2-deficient tumors.
- To identify treatments that selectively kill cancer cells while minimizing side effects.
- To explore mechanisms of cell death that circumvent PARPi resistance.
Main Methods:
- Literature review of existing and emerging cancer therapies.
- Analysis of treatment-induced cell death pathways in BRCA1/2-deficient models.
- Comparison of replication stress-dependent and -independent cell killing mechanisms.
Main Results:
- PARPi efficacy is linked to replication stress and chromosome instability.
- Alternative treatments are being investigated for BRCA1/2-deficient tumors.
- Rho-kinase (ROCK) and Polo-like kinase 1 (PLK1) inhibitors show potential for RS-independent, MN-independent cell killing.
Conclusions:
- Alternative therapies targeting ROCK and PLK1 may offer novel strategies against BRCA1/2-deficient tumors.
- RS-independent and MN-independent cell killing mechanisms could prevent or delay treatment resistance.
- Targeting distinct cell death pathways may overcome limitations of current PARPi treatments.
Related Concept Videos
The DNA Replication Fork
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
Homologous Recombination
DNA Damage Can Stall the Cell Cycle
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...

